Abstract
Bronchopulmonary neuroendocrine tumors (BPNETs) are the second most common subset of NETs after gastroenteropancreatic NETs. Historically, most clinical studies have excluded BPNETs during drug development and the data is often extrapolated from non-BPNETs. However, growing burden of BPNETs and the development of novel treatment strategies including targeted therapies and radiopharmaceuticals have paved the way for revisiting treatment strategies. In this review, we go over recent advances in the management of BPNETs and summarize consensus guidelines with the help of research data and clinical scenarios.
Full Text
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call